Patent ID: 7341717

Claim:
A method for inhibiting or downregulating Hepatitis C viral replication in an individual comprising the step of administering to an individual a pharmaceutically effective amount of an agent wherein said agent activates the activity of said human cellular protein gastrointestinal glutathione peroxidase or wherein said agent activates or stimulates the production of said human cellular protein gastrointestinal glutathione peroxidase, and wherein said agent is a combination of (i) selenium, or a selenium salt, and (ii) a retinoid selected from the group of: 9-cis retinoic acid, salts of 9-cis retinoic acid, C1-C10 alkyl esters of 9-cis retinoic acid, salts of C1-C10 alkyl esters of 9-cis retinoic acid, C1-C10 alkyl amides of 9-cis retinoic acid, salts of C1-C10 alkyl amides of 9-cis retinoic acid, 13-cis retinoic acid, salts of 13-cis retinoic acid, C1-C10 alkyl esters of 13-cis retinoic acid, salts of C1-C10 alkyl esters of 13-cis retinoic acid, C1-C10 alkyl amides of 13-cis retinoic acid, salts of C1-C10 alkyl amides of 13-cis retinoic acid, retinol, retinoic acid adlehyde, etretinate, N-(4-hydroxyphenyl) retinamide (4-HPR), 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437; AHPN), all-trans-retinoic acid, C1-C10 esters and amides of all-trans-retinoic acid, paraquat, 4-[E-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl]benzoic acid, 4-hydroxyphenylretinamide, and 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carboxamido]benzoic acid.